FDA designates another Alexion drug a 'breakthrough'

Shares of Alexion Pharmaceuticals rose as much as 6.7% on 24 October on news the FDA deemed the company's synthetic form of cyclic pyranopterin monophosphate (cPMP), known as ALXN1101, a breakthrough therapy – the second product in the firm's pipeline to win the status.